IBCCF · UFRJ

Gene Therapy and Viral Vectors Laboratory

Question. Study. Build.

Translational research in advanced therapies focused on innovative strategies for neuroprotection and axonal regeneration using rAAV vectors, CRISPR-Cas9, and mitotherapy.

About the lab Vector Core →

About LTGVV

The Gene Therapy and Viral Vectors Laboratory (LTGVV) was founded in 2021 at the Carlos Chagas Filho Biophysics Institute (IBCCF) of the Federal University of Rio de Janeiro (UFRJ). Our research focuses on developing and applying recombinant adeno-associated virus (rAAV) vectors and on the use of exogenous mitochondrial transplantation as therapeutic tools. We combine cutting-edge molecular engineering with gene editing technologies such as CRISPR/Cas9 to modulate gene expression and investigate cellular mechanisms associated with neurodegenerative diseases, particularly glaucoma.

Learn more about the lab

Explore

Two fronts, one mission

The laboratory

LTGVV

Translational research in advanced therapies — rAAV vectors, CRISPR-Cas9, mitotherapy, and neuroprotection. Meet the team, location, and capabilities.

Learn more

Production core

Vector Core

Brazil's first national rAAV vector production core, founded by Prof. Hilda Petrs-Silva at IBCCF. Serotypes, engineered capsids, and in vivo validation.

Learn more

Partners and affiliations

Building gene therapy as a network

IBCCF/UFRJ

UFRJ — Instituto de Biofísica Carlos Chagas Filho

INCT-INTERGEN

INCT de Terapia Gênica — INTERGEN

RENETA

ANVISA — Rede Nacional de Especialistas em Terapias Avançadas

ABTCELL-GEN

Associação Brasileira de Terapia Celular e Gênica

ASGCT

American Society of Gene and Cell Therapy

ESGCT

European Society of Gene and Cell Therapy

University of Florida

UMG

University of Göttingen Medical School

Agências de fomento

CNPq · CAPES · FAPERJ